Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.

Cancer 2007 May;109(9):1845-950

Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Background: A Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was performed in limited-disease small-cell lung cancer (LD-SCLC) to evaluate the efficacy and toxicity.

Methods: For untreated LD-SCLC patients, irinotecan (60 mg/m2, Days 1, 8, and 15) and cisplatin (40 mg/m2, Days 1 and 8) were repeated every 4 weeks for a maximum of 6 cycles. Thoracic radiotherapy of 1.8 Gy/day was begun on Day 1 of the second chemotherapy cycle, up to a total of 45 to 54 Gy. Prophylactic cranial irradiation (30 Gy in 10 fractions) was performed on patients with a complete response (CR).

Results: Thirty-three LD-SCLC patients were enrolled. The median age was 60 years and 31 patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Twelve (36.4%) patients had N3 disease. The response rate was 87.9%, with a CR rate of 45.5%. At a median follow-up period of 27 months the median progression-free survival (PFS) and overall survival (OS) were 14.4 and 26.1 months, respectively, with 2-year PFS and OS rates of 26.8% and 54.9%. The dominating toxicity was neutropenia, with grade 3-5 of 81.8%. The most common grade 3-5 nonhematologic toxicities were diarrhea (21.2%), anorexia (21.2%), and fatigue (21.2%). Grade 3-5 radiation esophagitis and pneumonitis occurred in 18.2% and 9.1% of patients, respectively. There were 2 treatment-related deaths from sepsis and radiation pneumonitis.

Conclusions: IP with early concurrent radiotherapy was effective and tolerable in untreated LD-SCLC.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22621DOI Listing
May 2007
9 Reads

Publication Analysis

Top Keywords

grade 3-5
12
concurrent radiotherapy
12
early concurrent
12
phase trial
8
trial irinotecan
8
mg/m2 days
8
limited-disease small-cell
8
ld-sclc patients
8
small-cell lung
8
irinotecan cisplatin
8
untreated ld-sclc
8
cisplatin early
8
lung cancer
8
patients
6
rate 455%
4
455% median
4
median follow-up
4
follow-up period
4
period months
4
months median
4

References

(Supplied by CrossRef)

Pignon et al.
N Engl J Med. 1992

Warde et al.
J Clin Oncol. 1992

Murray et al.
J Clin Oncol. 1993

Takada et al.
J Clin Oncol. 2002

Stupp et al.
Lung Cancer. 2004

Turrisi et al.
N Engl J Med. 1999

Skarlos et al.
Ann Oncol. 2001

Fukuda et al.
Cancer Res. 1996

Tamura et al.
Jpn J Cancer Res. 1997

Noda et al.
N Engl J Med. 2002

Therasse et al.
J Natl Cancer Inst. 2000

Similar Publications